FBDD Fragments Base Drugs Discovery | Design
   
               
Search    
18-Jul-2014
  IOTA publishes review with Genentech scientists describing the use of mechanism-informed phenotypic screening (MIPS) in oncology drug discovery
   
2-Apr-2014
  IOTA Pharmaceuticals in €7.8M consortium tackling neglected parasitic diseases
   
21-Sep-2012
  IOTA InFarmatik Press Release
   
22-Feb-2011
  IOTA announces KINOMED, a new partnership to accelerate protein kinase drug discovery Cambridge, UK / Odense, Denmark / Lund, Sweden, February 22, 2011
   
17-Aug-2009
  New consortium to develop drugs for neglected tropical diseases
   
23-Apr-2008
  IOTA announces SPR initiative with Beactica AB
   
21-Dec-2007
  IOTA announces FBDD screening services
   
21-Dec-2007
  IOTA announces collaboration with Vitas M-laboratory and new FBDD library:IOTA-Vitas 4000
   
5-Aug-2007
  IOTA Pharmaceuticals established; research centers in the UK, the Netherlands, and India.
   
3-Aug-2007
  IOTA announces FBDD Initiative with the VU University, Amsterdam
   
25-Sep-2007
  IOTA announces first FBDD product: IOTA Diverse 1500
   
 
 
IOTA’s Business Development offices are based in the St Johns Innovation Centre in Cambridge, Europe’s leading biotech city. Web-focussed, we offer business connectivity in the fragment-based drug design area to drug discovery companies, large and small.
 
Led by IOTA co-Founder Dr David Bailey, the business team has extensive experience working with large and small pharma, as well as international biotech companies.
 
 
IOTA Business
On-line LibrariesIOTA DesignIOTA Discovery
IOTA ScreeningIOTA ChemistryIOTA Services
Copyright © 2007 IOTA Pharmaceuticals  |   Site by Dots & Coms